Atsuyuki Saisyo

Atsuyuki Saisyo

Auto-generated profile, based on publicly available information

Atsuyuki Saisyo

Pharmacy Department, Yamaguchi University Hospital

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
ASAtsuyuki Saisyo
Atsuyuki Saisyo
HNHideaki Nakamura
Hideaki Nakamura
Jun FangJun Fang
Jun Fang
KTKenji Tsukigawa
Kenji Tsukigawa
Khaled GreishKhaled Greish
Khaled Greish
HMHiroshi Maeda
Hiroshi Maeda

26 July 2023 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
YKYasunobu Kouki
Yasunobu Kouki
NONaoto Okada
Naoto Okada
KSKosuke Saga
Kosuke Saga
MOMasakazu Ozaki
Masakazu Ozaki
ASAtsuyuki Saisyo
Atsuyuki Saisyo
TKTakashi Kitahara
Takashi Kitahara

11 February 2022 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
ASAtsuyuki Saisyo
Atsuyuki Saisyo
MYMichiya Yamaguchi
Michiya Yamaguchi
KKKoichi Kashibe
Koichi Kashibe
HIHaku Ishida
Haku Ishida
YHYasushi Hirano
Yasushi Hirano
TKTakashi Kitahara
Takashi Kitahara

17 April 2023 in American Journal of Infection Control
Verified
Journal Article
Closed access
TOTomoyuki Oka
Tomoyuki Oka
KKKyoji Kouda
Kyoji Kouda
NONaoto Okada
Naoto Okada
ASAtsuyuki Saisyo
Atsuyuki Saisyo
KKKouichi Kashibe
Kouichi Kashibe
TKTakashi Kitahara
Takashi Kitahara

1 July 2021 in YAKUGAKU ZASSHI
Verified
Journal Article
Closed access
PDF file
ASAtsuyuki Saisyo
Atsuyuki Saisyo
MTMiwako Takasago
Miwako Takasago
KWKazuki Wakabayashi
Kazuki Wakabayashi
MAMari Akiyama
Mari Akiyama
KKKyoji Kouda
Kyoji Kouda
TKTakashi Kitahara
Takashi Kitahara
To reduce the number of falls caused by hypnotic agents, the standardization of insomnia treatment was carried out at Yamaguchi University Hospital from April 2019. There were concerns that medical costs would increase due to the selected medicines―suvorexant and eszopiclone―being more expensive than conventional benzodiazepines. In this study, the standardization of insomnia treatment was evaluated by pharmacoeconomics. The costs of the hypnotic agents was considered, as was the cost of examination/treatment following falls. Effectiveness was evaluated as the incidence of falls within 24 hours of taking hypnotic agents. This analysis took the public healthcare payer's perspective. Propensity score matching based on patient background, showed that, per hospitalization the medicine costs of the recommended group increased by 1,020 yen, however, the examination/treatment costs following falls decreased by 487 yen when compared with the non-recommended group. Overall, the recommended group incurred costs of 533 yen more per hospitalization for patients prescribed hypnotic agents compared to the non-recommended group, but the incidence of falls for the recommended group was significantly lower than that in the non-recommended group (1.9% vs. 6.3%; p<0.01). These results suggest that in order to prevent the incidence of falls by 1 case, it is necessary to increase costs by 12,086 yen which is the subthreshold cost for switching to the recommended medicine as standardization. The selection of recommended medicines may be a cost-effectiveness option compared with non-recommended medicines.

10 July 2021 in Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Verified
Journal Article
Open access
PDF file
MTMiwako Takasago
Miwako Takasago
ASAtsuyuki Saisyo
Atsuyuki Saisyo
KWKazuki Wakabayashi
Kazuki Wakabayashi
MAMari Akiyama
Mari Akiyama
YFYuko Fujii
Yuko Fujii
TKTakashi Kitahara
Takashi Kitahara
We developed a flowchart for standardizing insomnia treatment to prevent falls associated with hypnotic drug dosing in Yamaguchi University Hospital, and implemented it from April 2019. The first recommended drug was suvorexant, followed by eszopiclone. In November 2019, we conducted a questionnaire survey involving doctors and nurses regarding the effectiveness and convenience of the flowchart. Eighty-one percent of the participants responded positively. We also investigated the incidence of falls within 24 h after dosing hypnotics. The fall rate before and after the introduction of the flowchart was no significant difference as determined by propensity score matching of the patient background. However, the fall rate for patients who received the recommended drugs was 3.1% and that for patients who received the deprecated drugs was 5.7%. Therefore, the fall rate of patients receiving the recommended drugs was significantly lower than that of patients receiving the deprecated drugs. The introduction of this flowchart may thus help prevent patient falls.